Review



cinanserin hydrochloride  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Tocris cinanserin hydrochloride
    FIGURE 3 Time–response (a) and dose–response (b, c) curves of intraperitoneally administered nefopam (30 mg/kg) with or without pre-treatment with intra-nucleus raphe magnus injection of <t>cinanserin</t> (0.001 μg) during the formalin test. The data are presented as the number of flinches (a) or the percent of the control in each phase (b, c). Each line or bar represents the mean ± standard deviation of five rats. IP, intraperitoneal; NRM, nucleus raphe magnus. **p < 0.01 compared to the control (saline + saline) group, ††p < 0.01, †††p < 0.001 compared to the saline-pre-treated (saline + nefopam) group, by unpaired t-test.
    Cinanserin Hydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cinanserin hydrochloride/product/Tocris
    Average 94 stars, based on 12 article reviews
    cinanserin hydrochloride - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Antinociceptive effects of nefopam activating descending serotonergic modulation via 5-HT2 receptors in the nucleus raphe magnus."

    Article Title: Antinociceptive effects of nefopam activating descending serotonergic modulation via 5-HT2 receptors in the nucleus raphe magnus.

    Journal: European journal of pain (London, England)

    doi: 10.1002/ejp.2173

    FIGURE 3 Time–response (a) and dose–response (b, c) curves of intraperitoneally administered nefopam (30 mg/kg) with or without pre-treatment with intra-nucleus raphe magnus injection of cinanserin (0.001 μg) during the formalin test. The data are presented as the number of flinches (a) or the percent of the control in each phase (b, c). Each line or bar represents the mean ± standard deviation of five rats. IP, intraperitoneal; NRM, nucleus raphe magnus. **p < 0.01 compared to the control (saline + saline) group, ††p < 0.01, †††p < 0.001 compared to the saline-pre-treated (saline + nefopam) group, by unpaired t-test.
    Figure Legend Snippet: FIGURE 3 Time–response (a) and dose–response (b, c) curves of intraperitoneally administered nefopam (30 mg/kg) with or without pre-treatment with intra-nucleus raphe magnus injection of cinanserin (0.001 μg) during the formalin test. The data are presented as the number of flinches (a) or the percent of the control in each phase (b, c). Each line or bar represents the mean ± standard deviation of five rats. IP, intraperitoneal; NRM, nucleus raphe magnus. **p < 0.01 compared to the control (saline + saline) group, ††p < 0.01, †††p < 0.001 compared to the saline-pre-treated (saline + nefopam) group, by unpaired t-test.

    Techniques Used: Injection, Control, Standard Deviation, Saline



    Similar Products

    cinanserin hydrochloride  (Tocris)
    94
    Tocris cinanserin hydrochloride
    FIGURE 3 Time–response (a) and dose–response (b, c) curves of intraperitoneally administered nefopam (30 mg/kg) with or without pre-treatment with intra-nucleus raphe magnus injection of <t>cinanserin</t> (0.001 μg) during the formalin test. The data are presented as the number of flinches (a) or the percent of the control in each phase (b, c). Each line or bar represents the mean ± standard deviation of five rats. IP, intraperitoneal; NRM, nucleus raphe magnus. **p < 0.01 compared to the control (saline + saline) group, ††p < 0.01, †††p < 0.001 compared to the saline-pre-treated (saline + nefopam) group, by unpaired t-test.
    Cinanserin Hydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cinanserin hydrochloride/product/Tocris
    Average 94 stars, based on 1 article reviews
    cinanserin hydrochloride - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    cinanserin  (Tocris)
    94
    Tocris cinanserin
    FIGURE 3 Time–response (a) and dose–response (b, c) curves of intraperitoneally administered nefopam (30 mg/kg) with or without pre-treatment with intra-nucleus raphe magnus injection of <t>cinanserin</t> (0.001 μg) during the formalin test. The data are presented as the number of flinches (a) or the percent of the control in each phase (b, c). Each line or bar represents the mean ± standard deviation of five rats. IP, intraperitoneal; NRM, nucleus raphe magnus. **p < 0.01 compared to the control (saline + saline) group, ††p < 0.01, †††p < 0.001 compared to the saline-pre-treated (saline + nefopam) group, by unpaired t-test.
    Cinanserin, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cinanserin/product/Tocris
    Average 94 stars, based on 1 article reviews
    cinanserin - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 3 Time–response (a) and dose–response (b, c) curves of intraperitoneally administered nefopam (30 mg/kg) with or without pre-treatment with intra-nucleus raphe magnus injection of cinanserin (0.001 μg) during the formalin test. The data are presented as the number of flinches (a) or the percent of the control in each phase (b, c). Each line or bar represents the mean ± standard deviation of five rats. IP, intraperitoneal; NRM, nucleus raphe magnus. **p < 0.01 compared to the control (saline + saline) group, ††p < 0.01, †††p < 0.001 compared to the saline-pre-treated (saline + nefopam) group, by unpaired t-test.

    Journal: European journal of pain (London, England)

    Article Title: Antinociceptive effects of nefopam activating descending serotonergic modulation via 5-HT2 receptors in the nucleus raphe magnus.

    doi: 10.1002/ejp.2173

    Figure Lengend Snippet: FIGURE 3 Time–response (a) and dose–response (b, c) curves of intraperitoneally administered nefopam (30 mg/kg) with or without pre-treatment with intra-nucleus raphe magnus injection of cinanserin (0.001 μg) during the formalin test. The data are presented as the number of flinches (a) or the percent of the control in each phase (b, c). Each line or bar represents the mean ± standard deviation of five rats. IP, intraperitoneal; NRM, nucleus raphe magnus. **p < 0.01 compared to the control (saline + saline) group, ††p < 0.01, †††p < 0.001 compared to the saline-pre-treated (saline + nefopam) group, by unpaired t-test.

    Article Snippet: The following drugs were used: formalin (Sigma Aldrich), nefopam hydrochloride 3, 10 or 30 mg/kg (Acupan®; Pharmbio Korea Co. Ltd.); dihydroergocristine 30 μg (nonselective 5- HT receptor antagonist; Tocris Cookson Ltd.); and cinanserin hydrochloride 0.001 μg (non- selective 5- HT2 receptor antagonist; Tocris Cookson).

    Techniques: Injection, Control, Standard Deviation, Saline